Short Interest in Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Grows By 113.1%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 745,300 shares, a growth of 113.1% from the February 28th total of 349,800 shares. Based on an average daily volume of 7,170,000 shares, the short-interest ratio is currently 0.1 days. Approximately 7.5% of the shares of the stock are sold short.

Petros Pharmaceuticals Price Performance

Shares of Petros Pharmaceuticals stock traded down $0.02 during midday trading on Friday, reaching $0.09. The company had a trading volume of 14,877,153 shares, compared to its average volume of 9,002,184. The stock has a fifty day simple moving average of $0.18 and a 200 day simple moving average of $0.28. The company has a market capitalization of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of 2.04. Petros Pharmaceuticals has a 1-year low of $0.05 and a 1-year high of $1.52. The company has a current ratio of 0.85, a quick ratio of 0.74 and a debt-to-equity ratio of 1.58.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).